Topic: Efficacy and Safety of Trastuzumab Deruxtecan in Patient with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Objectives: 

1. To understand the design and inclusion criteria of the DESTINY-PanTumor02 Phase II trial investigating trastuzumab deruxtecan in patients with HER2-expressing solid tumors.

2. To interpret the following results: objective response rates, duration of response, and progression-free survival across tumor types.

3. To understand the safety profile of trastuzumab deruxtecan.

Speaker: Dr. Samantha Summers

Session date: 
10/27/2025 - 6:30pm to 8:00pm EDT
Location: 
See outlook invite
Greenville, SC 29605
United States
See map: Google Maps
Add to calendar: 
  • 1.50 AMA PRA Category 1 Credit(s)™
    The University of South Carolina School of Medicine Greenville designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The University of South Carolina School of Medicine Greenville is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  • 1.50 Attendance
Please login or register to take this course.